Drug Profile
DNA lipid complex gene delivery systems - Valentis
Latest Information Update: 21 May 2007
Price :
$50
*
At a glance
- Originator Nonindustrial source; Valentis
- Developer DSM; Valentis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Cystic fibrosis; Head and neck cancer; Ischaemic heart disorders; Osteoarthritis; Peripheral vascular disorders; Rheumatoid arthritis; Solid tumours; Transplant rejection